<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247622</url>
  </required_header>
  <id_info>
    <org_study_id>1.1</org_study_id>
    <nct_id>NCT02247622</nct_id>
  </id_info>
  <brief_title>Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis</brief_title>
  <official_title>Primary Sclerosing Cholangitis Telomere Length</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PSC is a chronic cholestatic disorder. The investigators intend to study some telomere
      parameters and telomere length in order to predict a premalignant state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary sclerosing cholangitis (PSC) and colitis are chronic inflammatory disorders with
      malignant potential. Telomerase is an enzyme complex that lengthens telomeres and has
      enhanced expression in numerous malignancies. In this study, we evaluated the telomerase gene
      copy number, telomere length, cells in senescence, aneuploidy and additional parameters of
      telomere dysfunction from peripheral blood lymphocytes of patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Telomere length</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of cells with increased telomerase RNA component (TERC) expression</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>IBD</arm_group_label>
    <description>patients with inflammatory bowel disease, study group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PSC</arm_group_label>
    <description>patients with primary sclerosing cholangitis, study group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary sclerosing cholangitis and inflammatory bowel disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  documented PSC and inflammatory bowel disease

        Exclusion Criteria:

          -  under 18 years, above 80 y

          -  known active malignancy

          -  decompensated cirrhosis

          -  patients who cannot sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ido Laish, MD</last_name>
    <phone>+972-549477261</phone>
    <email>ido.laish@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ido Laish, MD</last_name>
      <email>ido.laish@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ido Laish, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 19, 2014</last_update_submitted>
  <last_update_submitted_qc>September 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>ido laish</investigator_full_name>
    <investigator_title>Md.</investigator_title>
  </responsible_party>
  <keyword>telomeres</keyword>
  <keyword>PSC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

